TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02326727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: General Anesthesia
Study: NCT02719392

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo control is an inactive sugar pill that mimics the active comparators in appearance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo control is an inactive sugar pill that mimics the active comparators in appearance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
Study: NCT01929200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-year treatment with icotinib
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-year treatment with icotinib
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
Study: NCT01406600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant hCG (Ovidrel®)
Description: Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant hCG (Ovidrel®)
Description: Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
Study: NCT00400712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical rehabilitation
Description: two weeks intensive physical rehabilitation
Study: NCT00067470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylgalactosamine 4-sulfatase
Study: NCT00672360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
Study: NCT00533429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
Study: NCT03658408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Description: Oral tablet of 2.5 mg given 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.5 mg sugar pill given orally 4 times a day
Study: NCT00533429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
Study: NCT04257071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OOP Cost Communication and Optimization
Description: OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
Study: NCT03990649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soticlestat matching placebo tablets
Study: NCT00973986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
Study: NCT01808768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcaftadine
Description: Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
Study: NCT01574859

Intervention type: OTHER
Intervention: levothyroxine
Description: titration of T4 according to biochemical values
Study: NCT01611831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT in group
Description: A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improved treatment as usual by General Practitioners
Description: General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
Study: NCT00540748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 5 U i.v. during surgical abortion
Study: NCT02582086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOR15001L7
Description: Active cream with 5% 15019L0

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Cream with 0% 15019L0
Study: NCT02829697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.
Study: NCT03076125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCORRE
Description: 3 components based on the Health Belief Model

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention-Control Activity
Description: sexual health education
Study: NCT01539785

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary citoreduction
Description: The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
Description: If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
Study: NCT05816967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medication review and discharge counseling
Description: Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
Study: NCT00533429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study: NCT04111172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Description: Given as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Description: Given as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Description: Given as intramuscular injection
Study: NCT03472599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genital Nerve Stimulation
Description: Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
Study: NCT00533429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study: NCT02204514

Intervention type: PROCEDURE
Intervention: Surgery for external snapping hip
Study: NCT02195817

Intervention type: DRUG
Group type: OTHER
Intervention: Selincro® 18 mg with continuous psychosocial support: Cohort A

Intervention type: OTHER
Group type: OTHER
Intervention: Initial psychosocial support: Cohort B
Study: NCT00936117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 200 mg (liquid) by mouth 3 times per day.
Study: NCT00866515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole + GW642444M
Description: Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + GW642444M
Description: Placebo to match D1-6 + GW642444M 25ug single dose on D5
Study: NCT00533429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: 15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily
Study: NCT02072954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine Sublingual Tablets 10 mg
Description: White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine Sublingual Tablets 10 mg
Description: Round, white to off-white sublingual tablets, with 10 on one side within a circle
Study: NCT02236793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone PDGF-BB
Study: NCT02438215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX4204
Description: IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
Study: NCT02236793

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study: NCT03685526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cinenses Lung Volume Reduction Reverser System
Description: Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
Study: NCT05651217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable urinary catheter
Description: The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: super smooth antibacterial urinary catheter
Description: the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
Study: NCT04509323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A for Injection
Description: Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
Study: NCT04461028

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal bupivacaine
Description: 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine with Dexamethasone Solution
Description: 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
Study: NCT02491398

Intervention type: DRUG
Intervention: Bendamustine + Rituximab

Intervention type: DRUG
Intervention: Bendamustine + Rituximab
Study: NCT03119818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phosphorus (31P) magnetic resonance spectroscopy
Description: Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
Study: NCT03027141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face recognition task
Description: Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face recognition task
Description: Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
Study: NCT04930211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-Lidocaine
Description: Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-Lidocaine
Description: Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
Study: NCT02428972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
Study: NCT04323150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed suction systems
Description: Closed suction systems are using for prevention of the ventilator-associated pneumoniae

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional suction system
Description: The using of open (conventional) suctioning
Study: NCT05015738

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional education
Description: Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Education supported by digital tools
Description: Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
Study: NCT03245580

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Core Liver Biopsy
Description: Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Core Liver Biopsy
Description: Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
Study: NCT02829697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.
Study: NCT02318771

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT
Study: NCT00232180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone administered on top of background standard heart failure therapy